Fifteen-year follow-up of Italian families affected by arginine glycine amidinotransferase deficiency by unknown
RESEARCH Open Access
Fifteen-year follow-up of Italian families
affected by arginine glycine
amidinotransferase deficiency
Roberta Battini1*, M. Grazia Alessandrì1, Claudia Casalini1, Manuela Casarano1, Michela Tosetti2
and Giovanni Cioni1,3
Abstract
Background: Arginine:glycine amidinotransferase deficiency (AGAT-d) is a very rare inborn error of creatine synthesis
mainly characterized by absence of brain Creatine (Cr) peak, intellectual disability, severe language impairment and
behavioural disorder and susceptible to supplementary Cr treatment per os. Serial examinations by magnetic
resonance spectroscopy are required to evaluate Cr recovery in brain during treatment of high doses of Cr per os,
which have been proved beneficial and effective in treating main clinical symptoms.
A long term study with detailed reports on clinical, neurochemical and neuropsychological outcomes of the first
Italian patients affected by AGAT-d here reported can represent a landmark in management of this disorder thus
enhancing medical knowledge and clinical practice.
Results: We have evaluated the long term effects of Cr supplementation management in four Italian patients
affected by AGAT-d, correlating specific treatments with serial clinical, biochemical and magnetic resonance
spectroscopy examinations as well as the neuropsychological outcome by standardized developmental scales.
Consecutive MRS examinations have confirmed that Cr depletion in AGAT-d patients is reversible under Cr
supplementation. Cr treatment is considered safe and well tolerated but side effects, including weight gain and
kidney stones, have been reported.
Conclusions: Early treatment prevents adverse developmental outcome, while patients diagnosed and treated
at an older age showed partial but significant cognitive recovery with clear improvements in adaptive functioning.
Keywords: Creatine synthesis defect, Magnetic resonance spectroscopy, Creatine supplementation, Longterm
outcome, AGAT deficiency
Background
Arginine:glycine amidinotransferase (AGAT, OMIM
602360) deficiency (AGAT-d) is a very rare inborn error
of creatine (Cr) synthesis described in 2000 in an Italian
family and successively confirmed by molecular and
enzymatic analysis [1, 2]. This disorder is caused by a
deficiency of the first enzyme involved in Cr synthesis
(Fig. 1), resulting in a commonly recognized biochemical
pattern represented by low Guanidinoacetic acid (GAA)
concentrations in plasma and urine and low/undetectable
brain Cr detectable by magnetic resonance spectroscopy
(MRS). Main clinical symptoms of this disorder are intellec-
tual disability, severe language impairment and behavioural
problems. Similar to guanidinoacetate-methyltransferase
deficiency (GAMT-d), another Cr synthesis defect, it is
susceptible of supplementation therapy with high doses of
Cr monohydrate per os [3–6].
Since the first reports on two Italian families [1, 2, 6]
15 years ago, only 16 patients from eight families of
different ethnic origins have been diagnosed [7].
There is a substantial lack of information on the outcome
of these patients, due to recent detection of disease, limited
number of years of substitutive treatment and paucity of
identified patients. So far, a longitudinal 9-year study on a
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AGAT patient [8] and a recent review with some data on
all AGAT-d patients identified worldwide [7] have been
reported. In particular, this review confirms that the main
clinical symptoms of the disease are present in all patients
and reveals that myopathic symptoms are also present in
about half of them, particularly in patients with a late diag-
nosis (from 6 to 23 years). Seizures and behavioural prob-
lems have also been reported in a few cases [7]. Chronic Cr
supplementation of varying dosages, ranging from 100 to
800 mg/Kg/day, restores brain Cr to 60–95% of normal in
all patients monitored by MRS, improving cognitive and
motor symptoms [7], with the exception of one patient in
which it increased only to 18% of normal even after 7 years
of supplementation [7, 9]. Since blood and cerebral Cr con-
centrations during treatment have not been reported in all
patients, it is not possible to establish a correlation, if any,
between brain and blood levels. This information would be
interesting in order to tailor treatments for each patient,
thus avoiding high dosages and potential metabolic dysreg-
ulation. Therefore in this paper, we report the clinical data
observed in our AGAT-d patients over a long period.
In fact, Cr treatment in these patients was pioneering
and required constant adjustments according to clinical
and biochemical evidence. During treatment, we attempted
to answer the following questions which arose over time
relative to patient outcome: a) which is the best dosage
regimen? b) how long are brain Cr recovery times? c) how
is neuropsychological impairment modified over time? d) is
long term treatment safe for patients?
We updated previous data collected over time from
the first Italian patients [1, 2, 6, 10–12] and we reviewed
their long term outcomes in relation to clinical, neuro-
psychological, biochemical and toxicological findings
after 10/15 years of Cr supplementation per os.
Methods
Study sample
Four patients from two related families are included in
this report: two sisters (P1, P2, case index), diagnosed at
4 and 6 years respectively [1], and their brother (P4,
neonatal diagnosis) [10] from family I and one male
(P3) from family II, diagnosed at 2 years [6]. Their pedigree
is already reported in our previous publication [6].
These subjects presented hyposomia, mild hypotonia,
clumsiness, developmental delay with mild or moderate in-
tellectual disability and severe language impairment [1, 6].
This research is part of a more general project on the
treatment of primary Cr defects approved by the Stella
Maris Institute Ethics Committee. Informed written con-
sent was obtained from parents of each patient, before
starting treatment trial with Cr per os.
DNA sequence analysis of AGAT was performed on
each patient [2, 6, 10] and in order to understand better
the role of enzymes involved in Cr metabolism disorders,
a study of GAMT (OMIM 601240) was also performed on
the two families [6].
Biochemical analyses of Cr and GAA in plasma and
urine were performed in order to monitor Cr status in
body fluids and therapeutic compliance of patients
through follow-up. Galenic Cr-monohydrate supplemen-
tation per os in P1-P3 was initially administered at
400 mg/kg subdivided in 3 doses daily. After 6 years, this
was reduced to 200 mg/kg for P1, P2 and to 300 mg/kg
for P3 [11]. After about 10 years, it was further reduced to
100 mg/kg/die in P1, P2, P3, subdivided in two admin-
istrations. This dosage has been maintained until the
present. Treatment of P4 started with Cr at 100 mg/Kg/day
at 4 months of life [10] and remained substantially un-
changed until the age of 10.
Since 2007, when the report on a 6-year outcome of
our first 3 AGAT-d patients was published [11], all
patients regularly underwent clinical (biochemical and
neuropsychological) and MRS assessments, annually
for P4 and every 18–24 months for the others.
Clinical assessment
Clinical assessment consisted of monitoring: i) auxological
data (weight, height and OFC); ii) routine laboratory eval-
uations (glycemia, BUN, creatininemia, hepatic enzymes,
and urine examination); iii) Cr levels in blood and urine
and plasma amino acids; iv) cognitive abilities by compre-
hensive neuropsychological evaluation.
Fig. 1 Metabolic pathway of creatine synthesis. Bars on the arrows indicate the blockage in AGAT-d
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In addition, considering the chronic high doses of Cr
supplementation, creatinine and BUN were also initially
evaluated every 6 months at home in order to monitor
renal function.
Muscle strength was assessed after 11 and 15 years of
follow-up by clinical grading scale (MRC scale).
Cr and GAA analysis in plasma and urine were per-
formed by GC/MS [10] and plasma amino acids by an
amino acid analyzer (JLC-500/V, Jeol, Japan).
Serial neuropsychological assessments were performed
initially by means Griffiths Scales, Performance Scales of
Wechsler Preschool and Primary Scale of Intelligence
(WPPSI), visuomotor integration abilities test, language
evaluation including productive and receptive vocabulary,
sentence comprehension, and sentence repetition test [1,
6, 10]. Successively, all patients were monitored by
Wechsler Intelligence Scale for children (WISC-r and
WISC-III), Wechsler Adult Scale of Intelligence (WAIS-r)
and WPPSI [12, 13]; in the last exam for P1-P3 by the
Wechsler Adult Scale of Intelligence–IV Edition [12, 14]
and for P4 by the Wechsler Intelligence Scale for
Children-IV Edition [13]. These scales give an overall as-
sessment of cognitive abilities for adults, young children
and adolescents, respectively; providing a total score of
Intelligence Quotient (TIQ) and four composite scores,
which measure specific cognitive domains: Verbal Com-
prehension (VC), Visual-perceptual Reasoning (VPR),
Working Memory (WM) and Processing Speed (PS).
Adaptive functioning in motor, communication, daily living
and socialization domains was assessed using the Vineland
Adaptive Behaviour Scales (VABS) overtime [1, 6, 15].
MRS assessment
1H-MRS was performed with 1.5 T clinical scanner (LX
Signa Horizon 1.5 GE Healthcare, Milwaukee, WI,
USA) and data were acquired from voxel (VOI) of
3.4 cc placed in parietal cortical gray matter [1, 6, 10].
Since 2007, we have monitored all patients also by 31P-
MRS, performed in the same session using the same
MR system operating at 25.86 MHz. Data were col-
lected with a surface flexible spectroscopy coil placed
around the head at maximum diameter, applying a hard
pulse. Spectral width was 2500 Hz and 1024 complex
data points were sampled with a TR of 4 s, a flip angle
of 60 for a total of 128 averages [11, 16]. Phosphocrea-
tine (PCr) and other high-energy phosphates such as
inorganic phosphate (Pi) and nucleoside triphosphates
(gamma-ATP, alfa-ATP and beta-ATP) were measured
in terms of a ratio with respect to phosphodiester signal
(PDE) [11]. PDE signal was chosen as internal reference
since it demonstrated a steady signal amplitude in both
normal subjects and in patients in this study and
because this metabolite is not included in any known
metabolic circuit for cellular ATP production. Spectra
were processed with SAGE software package [11, 17];
pH was calculated from shift in resonance position of
inorganic phosphate (Pi) peak compared to resonance
position of PCr [11, 17].
Results
Clinical assessment
All patients showed a homozygous mutation c. 446 > A/
p.Trp149* (stop mutation) in AGAT [2, 6, 10]. P1, P2
and P3 with their parents and 10 additional subjects of
the pedigree were analysed by sequencing also GAMT. A
sequence variation in exon 6 (T209M) at nt position
4024C > T of GAMT was disclosed, resulting in an
amino acid change from threonine to methionine. The
T209M sequence variation (dbSNP: rs 17851582) was
carried heterozygously by 13 subjects and homozygously
by 2 subjects (P1 and her asymptomatic father). How-
ever, normality of GAMT activity confirmed that this
variation was non-pathogenic, without any clear conse-
quences on enzyme protein function [6].
Plasma and urine Cr levels at diagnosis, after 5 years
of Cr 200 mg/Kg/day (11-year follow-up) and 4 years of
Cr 100 mg/Kg/day (15-year follow-up) for P1, P2, P3,
and after 10-year follow-up for P4, respectively, are re-
ported in Table 1. These data are different from those
reported in the first papers on these patients [1, 6],
probably due to the different techniques adopted for
measuring low GAA and Cr concentrations. Cr levels in-
creased under supplementation at all dosages compared
to initial status, with highest concentrations at largest
doses used. This was more evident in urine samples where
very high levels of Cr, 4 to 10 times above the maximum
reference value, were observed. Plasma Cr concentrations
were otherwise within the normal range for dosages under
200 mg/kg/day.
Cr supplementation was reduced to 100 mg/kg/day in
two administrations for P1, P2 and P3 after 11 years of
treatment and have remained at this level until today,
when a total amount of 3 g/day was adopted based on
presumed daily need in humans [18].
Patient 4, supplemented with unchanged protocol
since the first month of life (100 mg/kg/day), showed
stable Cr levels in blood with a remarkable reduction in
urine at the last exam (after 10 years of treatment), in
line with the dose reduction due to weight gain, corre-
sponding to about 60–70 mg/kg/day (Table 1).
Fasting plasma amino acids analysis showed normal
results for all amino acids involved in Cr metabolic cycle
which could be affected by long term Cr supplementation.
During chronic Cr supplementation, auxological data rap-
idly increased in all symptomatic patients, raising in less than
one year from p 3–50 and to p 75–85 after 2 years of
treatment. On the contrary, the asymptomatic patient
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showed normal growth since the first months of life,
with similar increases after 2 years of treatment (about
4 years at age).
Weight gain in all patients increased to p 90–95 after
few years of chronic Cr administration and have remained
at this level until now, despite a low calorie diet.
In all patients, high body mass indexes (BMI) were
observed, especially in pre-pubertal age (Fig. 2), simi-
larly for muscle bulk and muscle strength (grade 5 of
MRC scale).
In the first years of therapy, patients presented polyuria
and polydipsia. In addition, an occasional and transient
diarrhea was observed when patients increased dosages to
adjust for weight gain.
Routine laboratory evaluations were normal and patients
did not show any other adverse effects.
Urinary sediment was also analyzed in all patients
and none presented urine crystals, except for P3, who,
at 10 years, had an episode of a kidney stone with no
symptoms and spontaneously remittance after abundant
Table 1 Plasma, urine and brain concentrations of Cr and GAA in AGAT-d patients at diagnosis and after different treatment
Cr dose (mg/kg/day) T0 T1 T2
GAA μM Cr μM Cr mM PCr/PDE Cr μM Cr mM PCr/PDE Cr μM Cr mM PCr/PDE
P U P U Brain P U Brain P U Brain
P1 n.d. 2.45 5.23 146 1.10 0.73 28.33 9,784 3.77 1.11 51.9 6,445 3.9 1.40
P2 n.d. 2.16 5.41 133 1.05 0.76 38.67 37,489 3.86 1.15 26.2 9,459 3.2 1.35
P3 0.10 1.34 4.59 138 1.33 0.76 136.0 44,736 3.56 0.86 31.5 756 3.5 0.87
P4a 0.13 0.54 16.22 25 0.15 n.a. 51.2 13,886 4.30 0.96 45.3 5,843 4.0 1.07
range: 0.22–3.14 56–698 18–141 200–5500 4.37+ 0.44 1.40+ 0.14
P plasma, U urine, n.d. not detectable, n.a. not available
aCr dose stable at 100 mg/kg/day overtime
Data were recorded at T0 (diagnosis), T1 (after 5 years of Cr 200, 300, 100 mg/Kg/day for P1-P2, P3 and P4, respectively) and at T2 (last observation at 100 mg/Kg/day
for all patients)
Fig. 2 BMI changes in AGAT-d patients during Cr supplementation. Values higher than p 90 were observed in all patients in pre-pubertal age and
have remained unchanged to the present
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hydration therapy. Daily urinary clearance and proteinuria
were normal. P3 was thereafter monitored by renal ultra-
sound and urine examination every 6 months for three
consecutive years, with no abnormal findings.
All patients have continued to participate in psycho-
motor and speech rehabilitation programs at home since
diagnosis (2–3 times a week). They presented residual
expressive speech problems, but achieved educational
milestones in secondary school with special-education
teachers, except for P4 who is now attending the fourth
grade of primary school without any special aid and with
a good profile. Educational and social level of family I,
as well as dialect influences, could partially account
for this problem. In addition, the environment of family
II (divorced, poorly-educated parents and relatives,
periods of incarceration of father and other factors), may
have influenced compliance in supplementation and
rehabilitation treatment and consequently cognitive
development of P3.
P1-P3 presented similar profiles on intelligence scales
consisting of a greater fall in subtests designed to assess
VC (VC Index, VCI) and nonverbal (VPR Index, VPRI)
cognitive skills, and relatively better scores in subtests
aimed at assessing WM (WM Index, WMI) and PS (PS
Index, PSI). In fact, in all three patients, PSI statistically
[14] differed from VCI and PRI and in P1 and P3 it also
diverged from WMI. Cognitive difficulties of P1-P3
mainly affected processes of reasoning and knowledge
building, both in verbal and nonverbal domains, while
they showed better skills in working memory, attention,
speed of execution and visual-motor integration (Fig. 3).
A different profile was observed in P4, indicating only a
slight fall in WMI, which was statistically lower than the
others indices [13]. In comparison with normal TIQ of
P4 (98), P1-P3 presented deficient scores (41, 50 and 61,
respectively), with extensive falls in investigated areas,
expression of intellectual disability which remained
stable over years and was more severe in the older girl
who started treatment after 6 years of age (Fig. 3).
However, P1 and P2, now 23 and 20 years respectively,
obtained a high-school diploma: the oldest obtained a
Hospitality Training Institute diploma and now works as
a waitress in a pizzeria, while her younger sister earned a
Biology Science Institute diploma and she is now studying
with support for admission to a university bachelor pro-
gram in biology. P3, now 18 years, is attending the last
year of high-school (Hospitality Training Institute) with a
lower profile than the other girls.
MRS assessment
Consecutive MRS examinations have demonstrated that
Cr depletion in AGAT-d patients is reversible under Cr
supplementation. To our knowledge, only our patients
were monitored by Proton (1H-) and Phosphorus (31P-)
MRS in the same session during their long-term follow-up.
Table 1 and Fig. 4 summarize the 1H-MRS and 31P-MRS
data during follow-up.
Initial dosage of Cr supplementation was 400 mg/kg/day,
corresponding to about 20 times daily Cr requirement
for P1- P3, while P4 started his supplementation with
a dose of 100 mg/kg/day. At 1H-MRS, an increase of
Cr/PCr cerebral content was observed rapidly after sup-
plementation, reaching over 90% in the three symptomatic
subjects [1, 6], while in P4, Cr replenishment peaked at
60–65% [10]. Reducing Cr daily dose to 200 mg/kg in
P1-P3 did not lead to any differences in tCr and PCr
except for an unexpected drop in PCr/PDE ratio from
1.32 to 0.83 in P3 after an abrupt Cr reduction to
Fig. 3 Psychometric evaluations by WAIS-IV or WISC-IV intelligence scales in AGAT-d patients after 15 years of clinical follow-up. Columns represent
the scores obtained from each patient in different domains which contribute to the Total Intelligence Quotient (TIQ). Verbal Comprehension Index
(VCI) and Visual-Perceptual Reasoning Index (PRI) in the asymptomatic patient were normal differently from his symptomatic relatives. Working Memory
Index (WMI) and Processing Speed Index (PSI) in symptomatic patients presented better skills than the others
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200 mg/kg/day. In order to avoid a further decrease
of brain Cr, daily supplementation was immediately
increased to 300 mg/kg/day [11].
During the following years, Cr daily supplementation
was reduced to 100 mg/Kg in P1-P3 with no substan-
tially differences in comparison to the highest doses
(Table 1). A slight decrease in brain tCr peak was ob-
served in P2 and P3 with a concomitant reduction in
PCr peak compared to the results after 1 year at
200 mg/Kg/day [11, 12].
Brain Cr and PCr/PDE values in P4 showed an un-
changed trend overtime, maintaining normal levels
within 1 SD. Pi, ATP and pH in the brain were stable
and within normal values in patients during all the
above-mentioned treatments.
Discussion
It has been well recognized that Cr supplementation is
able to restore brain pool in patients with AGAT-d but
unfortunately little information is available in terms of
dosage, clinical progression and disease outcome. This
study aimed at providing an update of results achieved
in 4 AGAT-d patients after 15 (P1-P3) and 10 years (P4)
of Cr supplementation, respectively.
Our experience tells us that the first critical step in
diagnosis of AGAT-d consists of a proper quantitative
Fig. 4 Brain Total Creatine (right axis, solid line) and PCr/PDE (left axis, dashed line) modifications recorded in the patients with different Cr
amount. Normative data in the bars are represented as mean + SD
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measure of Cr and GAA in body fluids. As reported in
the first paper by our group [1], misleading results could
arise from urine samples, where levels of two key metab-
olites were near the lower end of normal value range,
probably reflecting excretion of Cr assumed in food.
Improvements in diagnostic techniques have eliminated
this problem, and successive measurements in the same
patients demonstrated that Cr and GAA levels in
AGAT-d were below control range both in blood and
urine indicating that they are, together with cerebral Cr
levels, the best markers for AGAT-d.
The decision to set the initial dose at 400 mg/Kg/day
in five administrations was based on an adopted schedule
in a patient with GAMT deficiency, the first described
inborn error of Cr metabolism [19], where 50% replenish-
ment of brain Cr pool after 12 weeks of supplementation
was reported. Similar brain Cr restoration was observed in
our patients after 9 months of therapy, which resulted in
80% of normal [1] in gray matter and cerebellum, with
concomitant improvements in cognitive development and
other clinical symptoms.
Similar ameliorations have been observed in all the
other patients [8, 9, 20]; for one of them the dosage was
increased up to 800 mg/Kg/day and then reduced to
500 mg/kg/day without different replenishment of brain
Cr, while progress in cognitive development was noticed
after start of treatment [8].
Even though all patients showed clinical improvements
under Cr supplementation; in patients where treatment
started at a later age, an amelioration in muscle strength/
endurance [9, 20] and in adaptive functioning [9] was
limited, while cognitive and speech remained unchanged.
Taken together, these two findings support the hypothesis
that myopathy may be a clinical sign of disease only at an
older age [7, 20] and that irreversible brain damage occurs
when treatment is delayed. Our data seem to confirm this
hypothesis because all patients diagnosed at a young age
did not show muscle deficiency and cognitive recovery
was lower for patients older at diagnosis. In fact, TIQ of
P1 did not change despite brain Cr recovery. Conversely,
early treatment prevents adverse developmental outcomes,
as demonstrated in P4 [10, 12] and in the other young
patient who started treatment at 16.5 months [8]; both of
them, currently 11 and 12 years of life respectively, have
achieved normal development with excellent educational
milestones. According to previous assessments [12],
WISC-IV score in the asymptomatic patient was within
normal range, indicating that his intellectual development
proceeded typically overtime with a slight residual speech
impairment, also present to a greater degree in his sisters.
The placental Cr delivery to the foetus during pregnancy
is important for an adequate growth and a development in
normal conditions [21, 22], and crucial in Cr disorders, as
demonstrated by the normal clinical presentation at birth
of P4. Maternal supplementation during pregnancy could
have provided higher levels of Cr in the affected newborn,
but she refused any prior treatment as well as any prenatal
diagnosis. In order to correct Cr depletion, since the infant
was breastfed, we initially tried to supplement the mother’s
diet with Cr. Although this approach resulted in an in-
crease of Cr concentration in maternal milk, Cr increase in
the infant’s blood, urine and brain was unremarkable [10].
Considering the clinical results in our 4 patients and
taking into account the limitations of this study, some
recommendations based on the evidence might be useful
in the management of AGAT-d patients. Daily dose was
reduced initially to 200 mg/kg/day in P1 and P2 after
6 years, and in P3 after 5 years, respectively, with good
results [11]. Subsequently, based on MRS data obtained
in the youngest patient, daily supplementation of the 3
older patients was gradually reduced to 100 mg/Kg/day
with a parallel decrease of Cr levels in blood and urine,
but not in the brain where Cr and PCr/PDE remained
stable or decreased only slightly (Fig. 4). The slight
reduction in brain Cr levels observed at the dose of
100 mg/Kg/day in these patients seems to have no effect
on their cognitive performances, which are stable in the
same range (Fig. 3), Indeed, in the asymptomatic newborn,
in which the initial dosage was lower (100 mg/Kg), a 65%
Cr restoration in brain required a longer period (about
18 months) than in his affected relatives, in which about
90% of Cr replenishment was observed after 12 months of
therapy [1, 10]. Considering that the blood brain barrier is
more permeable in developing brain and Cr was well
absorbed in all patients, as demonstrated by Cr concentra-
tions in plasma, the differences in brain recovery time
observed in the 4 patients could be ascribed to the
different dosage regimens adopted. Low doses require
more time to restore Cr in brain to the highest possible
levels without affecting clinical improvement, thus
avoiding peripheral compartment overloading and pos-
sible toxic effects. These findings seem to be confirmed by
data of the other young AGAT-d patient [8], in which
doses higher than 400 mg/Kg did not improve Cr/NAA
ratio more than 70% of controls and increased the risk of
renal damage. In our patients, reduction of doses to less
than 100 mg/kg/day normalized Cr in blood and urine,
with the best profile in P4, who is biochemically similar to
his normal peers.
1H MRS acquisition of P4 at the age of 8 years showed
a slight reduction of cerebral Cr as in P3 at the same
age, but not in the female patients, despite their different
dosage regimens.
In our patients, 100% recovery of cerebral Cr seems
unfeasible, whatever treatment schedule was used; the
highest Cr replenishment was found in P4 at about
4 years (98%). Although timing dosages for all reported
AGAT-d patients are incomplete, we suppose that the
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principal factor accounting for this effect is the down
regulation of the transporter protein at high Cr concentra-
tions [5, 23]. However, in the mouse model of AGAT-d,
total Cr brain accumulation continues over time up to the
normal concentrations of wild-type mice [24], while in
AGAT-d patients brain Cr always remains below control
values. Partial recovery of cerebral Cr in patients could rep-
resent a missing amount deriving from cerebral AGAT-d
synthesis. Endogenous Cr synthesis contributes to brain
needs for a negligible part (no more than 20%) as demon-
strated by mouse models of Cr transporter (CrT) deficit
[24, 25], where it is reduced in both the cortex and hippo-
campus to about 18–20% of control groups. In addition,
brain Cr in CrT deficient patients is absent or strongly
reduced when assessed by 1H-MRS; thus supporting the
hypothesis that endogenous synthesis does not compensate
for loss of Cr deriving from periphery. These consider-
ations might account for the partial brain Cr replenishment
in AGAT-d patients which does not reach the same level
of controls and remains stable below 90% even when Cr
transport is forced with high doses. However, despite the
partial restoration of brain Cr pool, the clinical status of
these patients improve significantly during treatment and,
in the one who was early treated, typical somatic and
psychomotor development was observed.
Considering the best dosage regimen, we can hypothesize
that oral Cr supplementation efficiently restores cerebral
levels even at lower doses, although more slowly, after a
short period at high doses (400 mg/kg/day) in older
patients or at 100 mg/kg/day in younger ones. The
small number of patients included in this study and
their common genetic background, affecting both the
clinical course and treatment response, do not permit
us to suggest clinical guidelines suitable for all patients
with AGAT-d. However, as in other rare inborn errors
of metabolism, each patient constitutes his/her own
control and for this reason the optimal dosage treatment
response is not an unquestionable statement. Furthermore,
clear evidence for the effect of Cr on clinical improvement
in AGAT-d patients arises from the observation that
patient status normalizes during treatment.
Conclusions
Despite the small number of patients, we conclude
that 100% recovery of cerebral Cr seems unfeasible,
whatever treatment schedule used, but there was no
correlation between Cr levels and cognitive improve-
ment. Cr treatment was well tolerated even at high
doses, although side effects of weight gain and kidney
stones were observed.
As indicated by the normal clinical development of
P4, an early diagnosis is recommended for a timely
treatment, suggesting the importance of NBS. Given
the lack of a reliable biomarker in bloodspot for this in-
born error of metabolism, it might be useful to consider
other new options of treatment, such as untargeted
metabolomics and/or genomic NBS. In the meantime,
we should take in account AGAT-d in all patients pre-
senting development delay, hypotonia, myopathy and
language impairment in order to allow for an early
diagnosis thus enabling treatment.
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